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Background: Despite heart failure being a substantial risk factor for stroke, few studies have evaluated the
predictive value of heart dysfunction for all-cause mortality in patients with acute ischemic stroke, in particular in
the elderly. The aim of this study was to investigate whether impaired heart function in elderly patients can predict
all-cause mortality after acute ischemic stroke or transient ischemic attack (TIA).
Methods: A prospective long-term follow-up analysis was performed on a hospital cohort consisting of n = 132
patients with mean age 73 ± 9 years, presenting with acute ischemic stroke or transient ischemic attack, without
atrial fibrillation. All patients were examined by echocardiography during the hospital stay. Data about all-cause
mortality were collected at the end of the follow-up period. The mean follow-up period was 56 ± 22 months.
Results: In this cohort, 58% of patients with acute ischemic stroke or TIA had heart dysfunction. Survival analysis
showed that heart dysfunction did not predict all-cause mortality in this cohort. Furthermore, in multivariate
regression analysis age (HR 5.401, Cl 1.97-14.78, p < 0.01), smoking (HR 3.181, Cl 1.36-7.47, p < 0.01), myocardial
infarction (HR 2.826, Cl 1.17-6.83, p < 0.05) were independent predictors of all-cause mortality.
Conclusion: In this population with acute ischemic stroke or TIA and without non-valvular atrial fibrillation,
impaired heart function does not seem to be a significant predictor of all-cause mortality at long-term follow-up.
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Ischemic stroke and heart failure are major causes of
morbidity and mortality [1]. Previous studies have sug-
gested that heart failure is associated with increased risk
of ischemic stroke [2-7]. Risk factors for heart dysfunc-
tion are also hypertension, coronary artery diseases and
diabetes mellitus. In a study of 1247 patients diagnosed
with heart failure, Alberts et al. found that the risk of
ischemic stroke was strongly increased shortly after the
diagnosis and returned to normal within 6 months [3].
On the other hand, Witt et al. reported that the risk of
suffering an ischemic stroke increased within the first
30 days after heart failure diagnosis and remained elevated* Correspondence: bjorn.andersson@vgregion.se
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distribution, and reproduction in any mediumduring the 5-year follow-up period [6]. The somewhat
different results of these two studies could be due to dif-
ferences in heart failure populations. Even though atrial
fibrillation is a well-recognized risk factor for both heart
failure and ischemic stroke [8-11], it is still unclear if
heart dysfunction per se, in the absence of atrial fibrilla-
tion, is associated with increased risk of ischemic stroke.
Moreover, it remains unknown whether heart dysfunction
per se may predict poor outcome in patients with acute
ischemic stroke or transient ischemic attack (TIA).
Heart failure was associated with poor prognosis and
dependency in ischemic stroke patients [12-15]. It is cur-
rently discussed whether there is an independent associ-
ation between low left ventricular ejection fraction (LVEF)
and mortality in patients with ischemic stroke. Such an as-
sociation between LVEF and mortality has been reported
in some studies but not in all [13,16].tral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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http://www.biomedcentral.com/1471-2377/13/122The purpose of this study was to investigate whether
heart dysfunction, as defined by echocardiographic find-
ings, in the absence of atrial fibrillation, may predict
long-term all-cause mortality in elderly patients with acute
ischemic stroke or TIA.
Methods
Study cohort
We performed a retrospective survival analysis of pa-
tients admitted to the Stroke Unit, at Department of
Medicine, Sahlgrenska University Hospital, in Gothenburg,
from February 9, 2005 through May 31, 2009. Due to
problems related to data management, no patients were
included from January 1, 2007 until September 6, 2007.
Patients with ischemic stroke or TIA were included if
an echocardiography was performed during hospital
stay. Patients with a medical history of atrial fibrillation,
or who were found to have atrial fibrillation on the 24 hours
cardiac monitoring after admission were excluded.
Stroke was diagnosed according to the World Health
Organization definition of stroke [17]. TIA was defined as a
neurologic deficit that resolved completely within 24 hours.
Within 24 hours of admission, a cerebral computer-
tomography (CT) scan was performed on all patients.
Treatment with antiplatelet drugs was initiated if the
CT scan excluded cerebral bleeding. On admission, stroke
severity was assessed by using National Institute of Health
Stroke Scale (NIHSS) [18,19]; functional status was esti-
mated by using Modified Rankin Scale (mRS) [20,21] at
3-month follow-up.
Heart function was measured by echocardiography. Heart
dysfunction was either categorized as systolic dysfunction
or diastolic dysfunction. Systolic dysfunction was defined
as LVEF <50% [22]. Diastolic dysfunction was defined as
a combination of following criteria: 1) LVEF ≥50%; 2)
Normal-sized left ventricle [LVDD ≤5.5 (cm)]; and 3) one
of the following criteria: left ventricular hypertrophy; E/A
ratio <0.8 or ≥1.5; S/D ratio <1 or >1; left atrium ≥34 (cm2)
[23]. Echocardiography was performed by an echocardiog-
raphy specialist who was blinded to the other variables
examined in the study and, moreover, was independent
of study team. Inter-observers were LVEF estimation/
Simpson 22/27%, diastolic/systolic volume 14/22%, 2D
analyzing (mitral ring) 13%, VTI LVOT 8%. Doppler
echocardiography was used to obtain transmitral flow
and pulmonary venous flow determined from the apical
four chamber view. To record transmitral flow, the
sample volume was carefully positioned at the tip of
the leaflets of mitral valve. The following variables were
evaluated as parameters of left ventricular filling: peak
of early diastolic (E) and late diastolic (A) flow velocity
(E/A ratio), and peak pulmonary venous flow velocity
during ventricular systole (S), peak pulmonary venous
flow velocity during ventricular diastole (D) (S/D ratio).All images were stored in the hospital central image
database for later review. The final diagnosis was vali-
dated by a cardiologist. The study was approved by the
Ethics Committee at the University of Gothenburg. The
study protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki.
Laboratory analyses at baseline
Serum-total cholesterol, hemoglobin, C-reactive protein
(CRP), serum creatinine (S-creatinine), glomerular filtra-
tion rate (GFR), and cardiac troponin T (cTNT) were
measured by routine laboratory methods within 24 hours
of hospital admittance.
Outcome data
Information on all-cause mortality was collected from
medical records and the Swedish populations register at
the end of the follow-up period.
Statistics
The results are presented as percentage/mean ± standard
deviation (SD). Student’s unpaired t-test and, for discrete
variables, the chi-square test, were used to assess statistical
significance. Kaplan-Meier curves and Cox proportional-
hazard regression model were used for survival analysis.
The hazard ratios (HR) with confidence intervals (CI)
and p-values are presented. p < 0.05 was regarded as sta-
tistically significant. The PASW Statistics 18 (SPSS Inc.,
Chicago, Illinois, USA) statistical package was used for
all statistical analyses.
Results
Patient characteristics at baseline
Totally, n = 932 patients with acute ischemic stroke or
TIA were admitted to the stroke unit. Among them, n = 132
patients with mean age 73 ± 9 were referred for echocar-
diography due to suspect onset of heart failure or due to
suspect cardiac embolism, other than atrial fibrillation.
N = 34 had documented atrial fibrillation and were thus
excluded. Of the patients with heart dysfunction had 61
diastolic dysfunction and 16 systolic dysfunction.
Of the included patients with echocardiography, 58%
were found to have heart dysfunction. Detailed clinical
characteristics of the study population are presented in
Table 1.
Survival data
The mean follow-up period was 56 ± 22 months (min 1,
max 92). At the end of the follow-up period, 39/132
patients had died. The all-cause mortality was 35% among
patients with heart dysfunction, and 22% among patients
with normal heart function (n.s.). All-cause mortality
was associated with higher age (p < 0.01), higher mRS
at 3-month follow-up (p < 0.01), high CRP (p < 0.05),
Table 1 Characteristics of the acute ischemic stroke or TIA cohort by heart dysfunction or normal heart function
Total Heart dysfunction Normal heart function P-values
n = 132 n = 77 n = 55
Age (mean ± SD) 73.3 ± 9.2 74.4 ± 8.0 71.7 ± 10.6 0.100
Male (%) 52.3 51.9 52.7 0.930
Stroke (%) 85.6 93.5** 74.5 0.002
TIA (%) 14.4 6.5** 25.5 0.002
NIHSS scores 3.4 ± 4.7 3.9 ± 5.1 2.9 ± 4.1 0.297
mRS at 3-months follow-up
≤2 (%) 84.7 78.9* 92.7 0.030
>2 (%) 15.3 21.1* 7.3 0.030
All-cause mortality (%) 29.5 35.1 21.8 0.100
Clinical examinations
Systolic BP (mmHg) (mean ± SD) 169.0 ± 29.5 170.0 ± 32.3 167.8 ± 25.4 0.680
Diastolic BP (mmHg) (mean ± SD) 94.2 ± 17.6 95.0 ± 19.6 93.1 ± 14.5 0.548
Heart rate (beats/min) (mean ± SD) 77.2 ± 18.0 77.8 ± 18.3 76.4 ± 17.8 0.660
Laboratory variables
S-Creatinine (μmol/L) (mean ± SD) 84.1 ± 38.2 86.3 ± 43.8 81.0 ± 28.5 0.444
CRP (mg/L) (mean ± SD) 16.2 ± 32.4 16.7 ± 34.3 15.6 ± 29.7 0.859
cTNT (μg/L) (mean ± SD) 0.06 ± 0.29 0.08 ± 0.37 0.03 ± 0.04 0.417
Echocardiogram parameters
LVEF (%) 57.6 ± 9.8 56.0 ± 12.0* 60.3 ± 3.2 0.017
LVDD (cm) (mean ± SD) 4.9 ± 0.8 4.9 ± 0.9 4.7 ± 0.7 0.438
Left atrium (cm2) (mean ± SD) 19.8 ± 4.4 20.7 ± 4.6** 18.3 ± 3.6 0.004
Right atrium (cm2) (mean ± SD) 16.2 ± 3.9 16.5 ± 4.2 15.7 ± 3.4 0.309
PA mmHg (mean ± SD) 31.0 ± 8.4 30.8 ± 6.9 31.4 ± 11.4 0.795
Stroke volume (mean ± SD) 72.7 ± 19.7 68.8 ± 18.5* 91.0 ± 15.7 0.037
E/A ratio (mean ± SD) 0.9 ± 0.4 0.9 ± 0.4 0.9 ± 0.3 0.988
S/D ratio (mean ± SD) 1.4 ± 0.5 1.4 ± 0.5 1.1 ± 0.1 0.324
Cardiovascular risk factors
Smoking (%) 14.4 19.6 8.3 0.102
Hypertension (%) 59.1 59.7 58.2 0.858
Diabetes mellitus (%) 18.9 16.9 21.8 0.476
Hypercholesterolemia (%)1 13.9 15.5 11.8 0.558
Cardiovascular diseases
Myocardial infarction (%) 15.9 19.5 10.9 0.184
Angina pectoris (%) 15.9 18.2 12.7 0.398
Comorbidity
Pulmonary embolism (%) 1.5 0.0 3.6 0.092
Previous ischaemic stroke (%) 17.4 19.5 14.5 0.461
eGFR <60 (mL/min) (%)2 32.3 38.9 23.1 0.063
Anaemia (%)3 11.7 13.2 9.6 0.541
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Table 1 Characteristics of the acute ischemic stroke or TIA cohort by heart dysfunction or normal heart function
(Continued)
Pre-stroke medications
ACE inhibitors (%) 19.7 22.1 16.4 0.416
Angiotensin receptor blockers (%) 18.2 14.3 23.6 0.170
Beta-blockers (%) 36.4 41.6 29.1 0.142
Diuretics (%) 26.5 28.6 23.6 0.527
Aspirin (%) 42.4 44.2 40.0 0.634
Warfarin (%) 0.8 1.3 0.0 0.396
Clopidogrel (%) 1.5 1.3 1.8 0.810
Aspirin + Dipyridamol (%) 1.5 1.3 1.8 0.810
Dipyridamol (%) 7.6 6.5 9.1 0.578
Post-stroke medications
ACE inhibitors (%) 30.5 34.2 25.5 0.283
Angiotensin receptor blockers (%) 23.7 21.1 27.3 0.408
Beta-blockers (%) 44.3 51.3 34.5 0.056
Diuretics (%) 32.8 34.2 30.9 0.691
Aspirin (%) 82.4 81.6 83.6 0.760
Warfarin (%) 8.4 7.9 9.1 0.808
Clopidogrel (%) 3.1 5.3 0.0 0.084
Aspirin + Dipyridamol (%) 2.3 3.9 0.0 0.136
Dipyridamol (%) 46.6 39.5 56.4 0.056
NIHSS, National Institutes of Health Stroke Scale; mRS, modified rankin scale; BP, blood pressure; S-Creatinine, serum creatinine; CRP, C-reactive protein; cTNT,
cardiac troponin T; LVEF, left ventricular ejection fraction; LVDD, left ventricular diastolic dimension; PA, pulmonary artery pressure; E/A ration, passive filling of the
ventricle (early [E] wave) and active filling with atrial systole (atrial [A] wave); S/D ratio, systolic and diastolic component of pulmonary vein; eGFR, estimated
glomerular filtration rate; ACE inhibitors; angiotensin-converting-enzyme inhibitors.
1Hypercholesterolemia defined as total serum-cholesterol >6 mmol/L.
2eGFR estimated by Cockcroft-Gault formula.
3Anaemia according to WHO definition, as hemoglobin <130 g/L (males) and hemoglobin <120 g/L (females).
*, P < 0.05 for comparison of heart dysfunction with normal heart function.
**, P < 0.01 for comparison between heart dysfunction with normal heart function.
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myocardial infarction (p < 0.05), pre-stroke angina pectoris
(p < 0.05), eGFR <60 (mL/min) (p < 0.05), anaemia (p < 0.05),
pre-stroke treatment with clopidogrel (p < 0.05) and no
post-stroke treatment with aspirin (p < 0.05) (for details
see Table 2).Predictors of mortality
In a univariate regression analysis of the whole ischemic
stroke and TIA cohort (n = 132), the following factors
were found to be significant indicators of poor survival:
age, mRS >2 at 3-month follow-up, pre-stroke anaemia,
CRP, smoking, pre-stroke myocardial infarction, and pre-
stroke angina pectoris. Use of post-stroke aspirin was
associated with better survival. However, when the vari-
ables which were significant in univariate analyses were
further tested in a multivariate regression model, only
age, smoking and pre-stroke myocardial infarction, were
independently associated with all-cause mortality, while
use of post-stroke aspirin was identified as a protectivefactor (Table 3). Heart dysfunction was not identified
as an independent predictor of all-cause mortality.
In patients with heart dysfunction (n = 77), univariate
regression analysis showed that age, NIHSS score,
mRS >2 at 3-month follow-up and previous myocardial
infarction were all significant prognostic indicators as-
sociated with poor survival. Use of post-stroke aspirin
was associated with better survival. When the signifi-
cant variables from this analysis were further tested in
the multivariate regression analysis (Table 4) only mRS
>2 at 3-month follow-up was found to be an independ-
ent predictor of all-cause mortality; use of post-stroke
aspirin was identified as protective factor.Discussion
This study investigated the impact of impaired heart func-
tion on long-term all-cause mortality in a population with
acute ischemic stroke or TIA. Our results show that heart
dysfunction does not seem to be a predictor of all-cause
mortality in this clinical setting.
Table 2 Characteristics of the acute ischemic stroke or
TIA cohort by survival at the end of the follow-up period
Non-survivors Survivors P-values
n = 132 n = 39 n = 93
Age (mean ± SD) 77.5 ± 6.8** 71.5 ± 9.6 0.001
Stroke (%) 97.4* 80.6 0.012
TIA (%) 2.6* 19.4 0.012
mRS at 3-months follow-up
≤2 (%) 69.2** 91.3 0.001
>2 (%) 30.8** 8.7 0.001
Laboratory variables
CRP (mg/L) 28.0 ± 48.9* 11.4 ± 21.2 0.012
Echocardiogram parameters
LVEF 55.0 ± 12.3* 58.8 ± 8.2 0.043
Cardiovascular risk factors
Smoking (%) 29.6** 9.1 0.009
Cardiovascular diseases
Myocardial infarction (%) 28.2* 10.8 0.012
Angina pectoris (%) 25.6* 11.8 0.048
Comorbidity
eGFR <60 (mL/min) (%)1 47.2* 26.1 0.023
Anaemia (%)2 21.1* 7.8 0.033
Pre-stroke medication
Clopidogrel (%) 5.1* 0.0 0.028
Post-stroke medication
Aspirin (%) 71.1* 87.1 0.029
Only variables that are significant are listed in the table.
mRS, Modified rankin scale; CRP, C-reactive protein; LVEF, left ventricular
ejection fraction; eGFR, estimated glomerular filtration rate.
1eGFR estimated by Cockcroft-Gault formula.
2Anaemia according to WHO definition, as hemoglobin <130 g/L (males) and
hemoglobin <120 g/L (females).
*, P < 0.05; **, P < 0.01 non-survivors compared with survivors.
Table 3 Univariate- and multivariate regression analyses
of all-cause mortality in the total ischemic stroke or TIA
cohort (n = 132)
Univariate HR 95% CI P-values
Age (years) 4.903 2.15-11.19 <0.000
mRS >2 at 3-months follow-up (%) 4.163 2.07-8.36 <0.000
Anaemia (%) 2.462 1.13-5.39 0.024
CRP (mg/L) 2.070 1.04-4.11 0.037
Smoking (%) 2.327 1.01-5.39 0.049
Myocardial infarction (%) 2.405 1.20-4.84 0.014
Angina pectoris (%) 2.530 1.23-5.22 0.012
Post-stroke Aspirin (%) 0.360 0.18-0.73 0.005
Heart dysfunction (%) n.s
Multivariate HR 95% CI P
Age (years) 5.401 1.97-14.78 0.001
mRS >2 at 3-months follow-up (%) n.s.
Anaemia (%) n.s.
CRP (mg/L) n.s.
Smoking (%) 3.181 1.36-7.47 0.008
Myocardial infarction (%) 2.826 1.17-6.83 0.021
Angina pectoris (%) n.s.
Post-stroke Aspirin (%) 0.312 0.13-0.77 0.011
mRS, Modified rankin scale; CRP, C-reactive protein.
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the most common diseases in elderly people, but also
two of the most common causes of death [1,4,19,24-26].
Some studies have suggested that a strong association
would exist between heart failure and ischemic stroke
[2-7]. For example, The Framingham study found heart
failure to be one of the major risk factors for ischemic
stroke [5]. Both CHADS2 score and CHADS2-Vasc score
[27] take heart failure into account as one of the risk
factors for stroke. However, these scores address heart
failure patients with atrial fibrillation. Since heart failure
often occurs in conjunction with atrial fibrillation, it is
difficult to estimate the exact contribution of each of
these factors to the risk of stroke and/or decreased
survival after stroke. Moreover, heart dysfunction,
cardiac remodeling and atrial fibrillation may all con-
tribute to the risk of ischemic stroke and affect the
prognosis thereafter.As previously shown [8-10], the incidence of atrial fib-
rillation, which increases with age [11,28], is not only an
independent risk factor for ischemic stroke, but also for
worse outcome after ischemic stroke. In one of our previ-
ously published works, on data from the Swedish Heart
Failure Registry, almost 50% of the patients with heart
failure had associated atrial fibrillation [24]. Thus, it is
difficult to study how heart dysfunction, beyond atrial
fibrillation, affects prognosis after acute ischemic stroke
or TIA.
At present, there are limited studies about impact the
effect of heart dysfunction, in the absence of atrial fibril-
lation, on the long-term prognosis of ischemic stroke. A
few previous studies suggested that neurologic deficits
induced by stroke are more severe in patients with heart
failure, regardless the type of heart dysfunction (systolic
or diastolic) [29]. In the Northern Manhattan stroke study
[7], evaluating 323 stroke patients from a mixed-ethnic re-
gion, heart failure was found to be a significant predictor
of mortality.
Thus, the impact of heart dysfunction per se, in the
absence of atrial fibrillation, on stroke and mortality is
less clear. In the present work, we aimed to assess if heart
dysfunction alone may affect the prognosis of ischemic
stroke or TIA.
In some recent studies heart failure was associated
with poor prognosis in ischemic stroke patients [12-16].
Table 4 Univariate- and multivariate regression analysis
of all-cause mortality in the acute ischemic stroke or TIA
cohort with heart dysfunction (n = 77)
Univariate HR 95% CI P-values
Age (years) 3.759 1.58-8.96 0.003
NIHSS score 1.123 1.03-1.23 0.012
mRS >2 at 3-months follow-up (%) 5.914 2.60-13.46 <0.000
Myocardial infarction (%) 2.641 1.14-6.10 0.023
Post-stroke Aspirin (%) 0.292 0.12-0.69 0.005
Multivariate HR 95% CI P
Age (years) n.s.
NIHSS score n.s.
mRS >2 at 3-months follow-up (%) 6.133 2.12-17.76 0.001
Myocardial infarction (%) n.s.
Post-stroke Aspirin (%) 0.174 0.06-0.54 0.003
mRS, Modified rankin scale; NIHSS, National Institutes of Health Stroke Scale.
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who have an incident ischemic stroke have higher risk
for midterm dependency and early mortality due to index
stroke severity. Heart failure seems even to be a predictor
for long-term mortality [13-16]. Underlying cardiovascular
risk factors such as hypertension, valvular disease and
coronary artery disease may explain worse prognosis in
patients with ischemic stroke and history of heart failure.
Regardless of LVEF in ischemic stroke patients, have heart
failure in some studies been found to be associated with
more severity, recurrence risk and early- and long-term
mortality [13].
Dependency has been reported to be associated with
heart failure, stroke severity and age [14] and it has re-
cently been demonstrated that heart failure, atrial fibril-
lation and prestroke dementia are risk factors for death
within 1 month of a stroke event [15].
In ischemic stroke patients with low LVEF (≤35) it seems
plausible that stroke severity, age and atrial fibrillation
are independent predictors for 1-year mortality [16].
To achieve this purpose our study design was straight-
forward by excluding patients with concomitant atrial
fibrillation. Our results indicate that heart dysfunction is
not an independent predictor of all-cause mortality dur-
ing long-term follow up in this cohort. Instead, we found
that higher age, smoking, and pre-stroke myocardial in-
farction and none use of post-stroke aspirin [30-32] are
independent predictors of mortality in patients with acute
ischemic stroke or TIA, without atrial fibrillation.
Lip et al. [33] found that previous stroke/TIA was a pre-
dictor of mortality and of the composite end-point of
stroke together with mortality in heart failure patients
without atrial fibrillation, especially during the first 30 days
following initial diagnosis of heart failure. The difference
between our study and the study of Lip et al. is that ourfollow-up time is longer. There are no data in the latter
study on echocardiography parameters, so LVEF cannot
be compared between the two studies.
It is worthwhile to point out that in our study only 7%
of the total acute ischemic stroke or TIA cohort had
LVEF ≤30%. This might be due to the fact that patients
with severe heart dysfunction often were associated atrial
fibrillation and therefore were excluded. Moreover,
patients with already known heart failure were not
regularly referred to echocardiography during hospital
stay in daily practice.
It may be hypothesized, that the lack of association be-
tween mortality and heart dysfunction/heart failure found
in the present study may be explained by less severe
strokes in the present population. Also many patients
were chronically treated with long-term statins and an-
tihypertensives, which may have had a beneficial effect
on outcome. Another conceivable mechanism may be
that non-valvular atrial fibrillation per se is a stronger
risk factor for mortality and dependency than heart fail-
ure. Since heart failure patients with non-valvular atrial
fibrillation were included in previous studies, but not in
the present one, our inconsistent results may at least
partly be explained by differences in study population.
Despite the limited sample size, our study is of poten-
tial interest since it examines the relationship between
heart dysfunction without concomitant non-valvular atrial
fibrillation – assessed immediately after onset of ischemic
stroke or TIA – and long-term stroke prognosis. More-
over, our study is to our knowledge among the first studies
to assess impact of heart dysfunction without concomitant
atrial fibrillation on prognosis of patients with acute ische-
mic stroke or TIA.Limitations
Our sample size was relatively small, since we excluded
all patients with atrial fibrillation and all patients not exam-
ined with echocardiography during hospital stay. Moreover,
a possible bias in the present study may be that patients
with previously known heart failure were not regularly
referred to echocardiography during hospital stay. More-
over, we did not control for atrial fibrillation or other comor-
bidities which might have debuted during the follow-up
period and thus, may affect long-term prognosis. Finally,
included patients did not have higher NIHSS points i.e.
less severe strokes.Conclusion
In conclusion, heart dysfunction, in the absence of atrial
fibrillation, does not seem to predict long-term all-cause
mortality in this population with acute ischemic stroke
or TIA. However, due to our small sample size any conclu-
sion must be drawn with great caution. A larger, prospective
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our findings.
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